ArriVent BioPharma Overview
Valuation check: AVBP's PEG ratio is 26.7, above the sector sector average of -2.26.
Get informed when a big investor buys or sells
+ Follow26.70
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for AVBP is 26.7. That is above the sector sector average of -2.26. Investors often review this figure alongside ArriVent BioPharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AVBP currently prints 26.7 for PEG ratio, while the sector average sits near -2.26. That is roughly 1282.6% above the sector mean. Large gaps often invite a closer look at ArriVent BioPharma's growth, margins, and balance sheet.
A PEG ratio of 26.7 for ArriVent BioPharma is not 'good' or 'bad' on its own. Compare it with the peer average (-2.26) and with AVBP's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting AVBP's PEG ratio (26.7), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
